Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic Syndrome

Most myelodysplastic syndromes (MDS) present with loss or gain of chromosomal material and less commonly show translocations as a sole abnormality. In addition, certain translocations are more commonly seen in MDS than others, but to our knowledge, the presence of t(6;15) has not been reported in MD...

Full description

Saved in:
Bibliographic Details
Main Authors: Saba F. Ali, Rebecca J. Sonu, Denis M. Dwyre, Brian A. Jonas, Hooman H. Rashidi
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:Case Reports in Hematology
Online Access:http://dx.doi.org/10.1155/2015/318545
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832568067351117824
author Saba F. Ali
Rebecca J. Sonu
Denis M. Dwyre
Brian A. Jonas
Hooman H. Rashidi
author_facet Saba F. Ali
Rebecca J. Sonu
Denis M. Dwyre
Brian A. Jonas
Hooman H. Rashidi
author_sort Saba F. Ali
collection DOAJ
description Most myelodysplastic syndromes (MDS) present with loss or gain of chromosomal material and less commonly show translocations as a sole abnormality. In addition, certain translocations are more commonly seen in MDS than others, but to our knowledge, the presence of t(6;15) has not been reported in MDS, specifically therapy-related MDS (t-MDS) cases. Patients with t-MDS, a group of heterogeneous stem cell related disorders resulting as a latent complication of cytotoxic and/or radiation therapy, generally tend to have a poorer prognosis than de novo MDS. We present a unique case of a patient who initially presented with acute myeloid leukemia (AML) with a normal karyotype and FLT3-ITD and NPM1 mutations. The patient was successfully treated with chemotherapy and an autologous bone marrow transplant but subsequently developed a new FLT3-ITD negative t-MDS with a unique translocation, t(6;15)(q12;q15), three years after transplant. To our knowledge, this unique sole translocation has never been reported in MDS or t-MDS and given her successful response to treatment and remission, presence of this translocation may have some prognostic value.
format Article
id doaj-art-4595ebaef15f4cd8bd1cf1867e0f4ae6
institution Kabale University
issn 2090-6560
2090-6579
language English
publishDate 2015-01-01
publisher Wiley
record_format Article
series Case Reports in Hematology
spelling doaj-art-4595ebaef15f4cd8bd1cf1867e0f4ae62025-02-03T00:59:50ZengWileyCase Reports in Hematology2090-65602090-65792015-01-01201510.1155/2015/318545318545Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic SyndromeSaba F. Ali0Rebecca J. Sonu1Denis M. Dwyre2Brian A. Jonas3Hooman H. Rashidi4Department of Pathology and Laboratory Medicine, University of California Davis Medical Center, Sacramento, CA 95817, USADepartment of Pathology and Laboratory Medicine, University of California Davis Medical Center, Sacramento, CA 95817, USADepartment of Pathology and Laboratory Medicine, University of California Davis Medical Center, Sacramento, CA 95817, USADepartment of Internal Medicine, Division of Hematology and Oncology, University of California Davis Medical Center, Sacramento, CA 95817, USADepartment of Pathology and Laboratory Medicine, University of California Davis Medical Center, Sacramento, CA 95817, USAMost myelodysplastic syndromes (MDS) present with loss or gain of chromosomal material and less commonly show translocations as a sole abnormality. In addition, certain translocations are more commonly seen in MDS than others, but to our knowledge, the presence of t(6;15) has not been reported in MDS, specifically therapy-related MDS (t-MDS) cases. Patients with t-MDS, a group of heterogeneous stem cell related disorders resulting as a latent complication of cytotoxic and/or radiation therapy, generally tend to have a poorer prognosis than de novo MDS. We present a unique case of a patient who initially presented with acute myeloid leukemia (AML) with a normal karyotype and FLT3-ITD and NPM1 mutations. The patient was successfully treated with chemotherapy and an autologous bone marrow transplant but subsequently developed a new FLT3-ITD negative t-MDS with a unique translocation, t(6;15)(q12;q15), three years after transplant. To our knowledge, this unique sole translocation has never been reported in MDS or t-MDS and given her successful response to treatment and remission, presence of this translocation may have some prognostic value.http://dx.doi.org/10.1155/2015/318545
spellingShingle Saba F. Ali
Rebecca J. Sonu
Denis M. Dwyre
Brian A. Jonas
Hooman H. Rashidi
Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic Syndrome
Case Reports in Hematology
title Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic Syndrome
title_full Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic Syndrome
title_fullStr Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic Syndrome
title_full_unstemmed Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic Syndrome
title_short Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic Syndrome
title_sort translocation 6 15 q12 q15 a novel mutation in a patient with therapy related myelodysplastic syndrome
url http://dx.doi.org/10.1155/2015/318545
work_keys_str_mv AT sabafali translocation615q12q15anovelmutationinapatientwiththerapyrelatedmyelodysplasticsyndrome
AT rebeccajsonu translocation615q12q15anovelmutationinapatientwiththerapyrelatedmyelodysplasticsyndrome
AT denismdwyre translocation615q12q15anovelmutationinapatientwiththerapyrelatedmyelodysplasticsyndrome
AT brianajonas translocation615q12q15anovelmutationinapatientwiththerapyrelatedmyelodysplasticsyndrome
AT hoomanhrashidi translocation615q12q15anovelmutationinapatientwiththerapyrelatedmyelodysplasticsyndrome